Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients

Sponsor
Zhongnan Hospital (Other)
Overall Status
Completed
CT.gov ID
NCT05808803
Collaborator
(none)
782
73

Study Details

Study Description

Brief Summary

The investigators included 782 HIV-infected patients from January 2016 to October 2020 Zhongnan Hospital of Wuhan University, whose AIDS diagnosis criteria met the "AIDS Diagnosis and Treatment Guide (2018 edition)" of Chinese Medical Association.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    782 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    A Single-center, Retrospective Cohort Study of Aberrant Myeloid Lineage Differentiation in HIV/AIDS Patients
    Actual Study Start Date :
    Jan 1, 2016
    Actual Primary Completion Date :
    Oct 31, 2020
    Actual Study Completion Date :
    Jan 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    HIV without leukemia

    HIV leukemia

    Outcome Measures

    Primary Outcome Measures

    1. The proportion of granulocytes and granulocyte/macrophage progenitors in myelogram of HIV/AIDS patients [2020]

      Flow cytometric immunophenotyping of an EDTA-anticoagulated BM aspirate specimen was performed. A standard BM assay with erythrocyte cell lysis was used for all BM aspirate specimens. Flow cytometric analysis was conducted using a FACS Canto II flow cytometer (Becton Dickinson, Sunnyvale, CA, USA).

    Secondary Outcome Measures

    1. Neutrophil counts in peripheral blood of HIV/AIDS patients [2020]

      Blood samples were drawn from patients undergoing routine diagnostic blood analysis at our institute by sterile venipuncture into tubes containing 5.4 mg of K2EDTA and analyzed by the automated hematology analyzer.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • HIV-infection
    Exclusion Criteria:

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Zhongnan Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Zhongnan Hospital
    ClinicalTrials.gov Identifier:
    NCT05808803
    Other Study ID Numbers:
    • 2021006K-HIV infection
    First Posted:
    Apr 11, 2023
    Last Update Posted:
    Apr 11, 2023
    Last Verified:
    Jan 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 11, 2023